VR1, Inc.

Ausanil is a rapidly effective (pain relief in under 3 minutes), affordable (less than 70c per dose) and safe medication (no drug on drug interactions, non habit forming, no systemic side effects) that is accessible over the counter without the need for a prescription. Launched in April 2014, Ausanil is now recommended by hundreds of neurologists and physicians, sold in pharmacies across the US and is available online. Thousands of patients are now using Ausanil to relieve their headache and migraine pain quickly and safely.

VR1 Inc. initially raised $2.5 million to fund product development, manufacture, product launch, marketing and the establishment of a sales force in the North East US. VR1 Inc. is seeking US$5M in the form of common stock in order to expand sales channels to major retail pharmacy channels nationwide, increase marketing and branding efforts and recruit key personnel.

• Competitive Advantage: Ausanil addresses migraine and severe headache pain up to 30x faster than other medications; marketed as an add-on to patients’ current treatment regimes, it presents a low threat to existing treatment products. Priced at 70c per dose, Ausanil is 50% less expensive than the largest non-prescription competitor, Excedrin, and is only a small percentage of the cost of prescription medications. Competitive pricing, absence of side effects experienced with other medications, including cardiac, liver and stomach problems, provide Ausanil with a distinct advantage.


• Traction: Ausanil was launched in March 2014 and has $200,000 in cumulative revenue as of May 2015 from online and pharmacy sales. 2015 revenue is on track to be 3X 2014 sales. Detailing medical professionals and attendance at key medical conferences has resulted in rapid growth in healthcare professional referrals, online and pharmacy sales. Targeted print, TV and radio marketing and PR campaigns resulting in National exposure in both industry and consumer publications (Pharmacy Times, Neurology Today, Shape Magazine, US News feature and others) continues to contribute to awareness among healthcare professionals and the consumer.
  Over 90% of doctors responding to a survey after using Ausanil for their patients indicated that they will continue to recommend Ausanil.


• Retail:
  United States: VR1 Inc. is currently in 400 pharmacies with heavy concentration in the North Eastern US. We are negotiating further agreements with distributors and pharmacy chains for increasing our retail outlet channels. Ausanil retails in the US for $34.95/bottle. Gross margins are at 91%. Normalized EBITDA margins are expected to be over 40%.
  International: VR1 Inc. is in negotiations with distributors in Canada, Europe, South Africa and India and has patent applications pending in all of these countries.

• Anjan Chatterjee (MD, CEO & Founder): Migaine sufferer, neurologist, 20 years of patient care and pharmaceutical development/Commercialization expertise with Merck and Pfizer.


• Michele Harris (COO & Head of Marketing): With background in direct marketing, sales and management joined Anjan to launch Ausanil.


• Joanne van Deusen (Sales Lead): 15 years sales and marketing experience growing market share for product portfolios in the pharmaceutical industry


• Reena Patel (Communications): 10 year PR veteran specializing in health care and pharmaceuticals

“My experience with Ausanil has been nothing short of a miracle!” Peggy P.
“My acupuncturist told me about Ausanil and I am so glad he did.” Lisa K.
“Ausanil delivers what it promises” Alexandra C.

Developed by Dr. Anjan Chatterjee, a neurologist and researcher with a decade of experience bringing neurological drugs to market for Merck and Pfizer, and migraine sufferer himself, Ausanil’s active ingredients are FDA approved as a homeopathic treatment with a long history of safety and efficacy. Ausanil has a substantial effectiveness rate at over 50%, falling well within the 38-60% rates achieved in clinical trials for prescription migraine medicines.
Ausanil is easy to use, even for those suffering with nausea, a common accompaniment to severe headache syndromes, works very quickly to relieve pain, has no systemic side effects associated with many of the most effective medications, is not addictive, requires no prescription and therefore no high-cost concerns or required visits to the doctors office.

Ausanil’s target market is defined as 45 million patients with severe headaches such as migraines, rebound headaches, Cluster headaches, Tension Type Headaches and Chronic Frequent Headaches who are dissatisfied with their treatment options. Ausanil’s US market opportunity is estimated at over $300 million at steady state by 2019 assuming a 10% penetration. Opportunities for expansion in the EU reflect a doubling of the addressable market. Asia, including China and India are additional large markets.

Available on further discussion with registered investors.

Major Non-prescription products – Execedrin, Tylenol, Sinol Nasal Spray
Prescription medications – Imitrex, Relpax

Available on further discussion with registered investors.

Disclosure: Investing in startups carries a high degree of risk. In general, financial and operating risks confronting both early and developmental-stage companies, as well as more mature expansion-stage companies are significant. Many emerging growth companies go out of businesses every year. It is difficult to know how companies will grow, if at all, or what changes may occur in the market. A loss of an investors entire investment is possible and no profit may be realized. Investors are responsible for conducting their own due diligence. * It should not be assumed that recommendations made in the future will be profitable or will equal the performance of securities in this list